Hemoglobinopathies Market Size, Share & Trends Report

Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Therapy, By Diagnosis, By Region, And Segment Forecasts, 2019 - 2026

  • Published Date: May, 2019
  • Base Year for Estimate: 2018
  • Report ID: 978-1-68038-736-0
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2017
  • Number of Pages: 100

Industry Insights

The global hemoglobinopathies market size was valued at USD 5.8 billion in 2018 and is expected to expand at a CAGR of 10.2% during the forecast period. Increasing cases of hemoglobinopathies, especially in regions such as Southeast Asia and Africa, is one of the major growth drivers. According to the World Health Organization (WHO) around 300,000 to 500,000 children born each year are affected by hemoglobin disorders. Sickle Cell Disease (SCD) and thalassemia account for more than half of the children born with Hb disorders.

Lack of awareness about these diseases leads to increase in death to survival ratio for patients suffering from SCD and thalassemia. However, increasing government and company initiatives for spreading awareness pertaining to hemoglobin variants diseases such as launch of the Cure Sickle Cell Initiative in September 2018 by the National Institutes of Health, is expected to boost market growth over the forecast period.

U.S. hemoglobinopathies market

Universal newborn screening programs particularly in the developed countries are effective measures to facilitate early detection of potentially harmful and fatal disorders, such as thalassemia and SCD in infants. For instance, in 2013, blood disorders division of the Centers for Disease Control and Prevention (CDC) along with the Association of Public Health Laboratories partnered on the hemoglobinopathies project for newborn screening health program. The project was launched with the aim to provide technical assistance to laboratories for assessment of hemoglobinopathies related complications and also imparting education to caregivers, healthcare workers and patients on the hemoglobinopathy screening programs. 

Increasing R&D activities aimed at developing novel therapeutics are also anticipated to contribute to market growth. The National Heart, Lung, and Blood Institute (NHLBI) which is part of National Institutes of Health (NIH) funds research programs for SCD to develop new ways to detect and treat the condition and also improve patient outcomes. Using advancements in gene-editing technologies, new procedures are being developed which involves editing or replacing the faulty SCD gene and transplanting the corrected gene back to the patients. Increase in grants for prevention and treatment of SCD through enactment of laws such as the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act, 2018 is also likely to help in better management of the condition.

Type Insights

The market is segmented into thalassemia (alpha and beta), sickle cell disease, and other hemoglobinopathies such as hereditary elliptocytosis. Gene mutations encoding the globins generate a variety of hereditary conditions producing blood disorders such as thalassemia and SCD.

SCD was the largest segment in terms of revenue in 2018. The segment is also expected to expand at a healthy CAGR over the forecast period, owing to the increasing efforts to improve patient awareness about the disorder and subsequent improvement in diagnosis and treatment.

Diagnosis Insights

Blood testing led the diagnosis segment in terms of revenue in 2018. The fact that blood testing is commonly used as the first-line screening method is a key contributor to its major market share. Genetic testing for diagnosis of SCD is expected to be the fastest growing segment over the forecast period due to its efficiency in precise diagnosis and monitoring. Pre-implantation Genetic Diagnosis (PGD) is expected to be the fastest growing segment for thalassemia diagnosis due to advantages associated with the diagnostic technique such as genetic monitoring during In-Vitro Fertilization (IVF).

Therapy Insights

On the basis of therapy, the market is categorized into blood transfusion, iron chelation therapy, bone marrow transplant, and others. Blood transfusion therapy accounted for the largest share of the market in 2018. Rise in government initiatives for increasing the number of blood donations is a high impact rendering driver for the hemoglobinopathies market.

Global hemoglobinopathies market

Permanent cure for hemoglobinopathies is the biggest requirement. The promising pipeline drugs kept on accelerated review are expected to fulfill the market requirement in near future. For instance, in July 2018, bluebird bio’s LentiGlobin therapy indicated for use in the treatment of sickle cell disease was granted accelerated assessment by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Regional Insights

North America led the overall market in terms of revenue in 2018 due to rising R&D investments by the key players, better reimbursement scenario, and presence of high-quality healthcare infrastructure.

Asia Pacific is expected to witness fastest growth during the forecast period. Introduction of indigenously-manufactured, low-cost diagnostic kits for thalassemia and sickle cell disease coupled with rising patient awareness level is expected to provide manufacturers with lucrative growth opportunities in near future.

Hemoglobinopathies Market Share Insights

Key market participants include Gamida Cell; Alnylam Pharmaceuticals; Sanofi; Sangamo Therapeutics Inc.; Global Blood Therapeutics; bluebird bio Inc.; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation.

Key players are focusing on implementing collaboration and licensing deals for sharing technical expertise related to hemoglobinopathies treating therapies. For instance, in January 2014, Sangamo Therapeutics, Inc. and Bioverativ announced global collaboration agreement that targeted the therapeutics development for hemoglobinopathies.

Report Scope

Attribute

Details

Base year for estimation

2018

Actual estimates/Historical data

2014 - 2017

Forecast period

2019 - 2026

Market representation

Revenue in USD Million & CAGR from 2019 to 2026

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Country Scope

U.S., Canada, Germany, U.K, France, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Singapore, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE

15% free customization scope (equivalent to 5-analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2026. For the purpose of this study, Grand View Research has segmented the global hemoglobinopathies market report on the basis of type, therapy, diagnosis, and region:

  • Type Outlook (Revenue, USD Million, 2014 - 2026)

    • Thalassemia

      • Alpha Thalassemia

      • Beta Thalassemia

    • Sickle Cell Disease

    • Other Hb Variants Diseases

  • Therapy Outlook (Revenue, USD Million, 2014 - 2026)

    • Thalassemia

      • Alpha Thalassemia

      • Beta Thalassemia

    • Sickle Cell Disease

    • Other Hb Variants Diseases

  • Diagnosis Outlook (Revenue, USD Million, 2014 - 2026)

    • Thalassemia

      • Alpha Thalassemia

      • Beta Thalassemia

    • Sickle Cell Disease

    • Other Hb variants diseases

  • Regional Outlook (Revenue, USD Million, 2014 - 2026)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • France

      • U.K.

      • Italy

      • Spain

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

      • Singapore

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified